Neuropathic Pain Clinical Trials
Here are the 6 most popular medical studies for neuropathic pain
Local Anesthetic
Exparel for Craniofacial Pain
This trial will test whether a single dose of Exparel (a long-acting pain reliever) can provide pain relief for up to 72 hours after surgery, compared to a placebo. The study will be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion.
Anti-epileptic drug
Gabapentin for Pain
This trial aims to determine how effective gabapentin is in reducing and resolving pain in children with severe brain-based developmental disabilities. These children often experience unexplained periods of pain and irritability, and the
Surface Acoustic Wave Patch Device
PainShield SAW Patch Device for Trigeminal Neuralgia
This is a double blinded randomized control trial of a Surface Acoustic Wave Patch device for the treatment of Trigeminal Neuralgia. This will be a crossover study for the group that receives the sham device. Subjects will be monitored for subjective criteria of pain and quality of life, as well as objective measurement of analgesic usage.
Immunomodulator
Intravenous Immunoglobulin (IVIG) for Neuropathic Pain
This project addresses a vexing problem that has alluded the best efforts of the medical/scientific community: treatment of resistant neuropathic pain. Neuropathic pain is common and includes conditions such as diabetic neuropathy, post herpetic neuralgia and post stroke pain and is believed to affect at least 3% of adults. Surveys of patients with neuropathic pain indicate that 60% do not receive adequate relief with current treatment. Results from recent laboratory and human studies reveal a new approach to treatment. This approach is based on the findings that neuroinflammation appears to be involved in development and maintenance of neuropathic pain. This study explores the effects of an immune-modulating blood-derived product, intravenous immunoglobulin (IVIG), in treating neuropathic pain. IVIG is thought to reduce neuroinflammation contributing to neuropathic pain. If successful, the study will provide important insights into pain mechanisms and a better understanding of how IVIG relieves neuropathic pain. Hypotheses: Reduction in neuroinflammation (NI) markers will co-vary with clinical indicators of pain relief Patients with higher levels of markers of NI will be more likely to respond to IVIG
Popular filter options for neuropathic pain trials
Diabetic Neuropathy Clinical Trials
View 17 Diabetic Neuropathy medical studies.
Procedure
Lidocaine Patch for Peripheral Neuropathy
This trial will compare a lidocaine patch to a placebo patch to see if the lidocaine patch helps reduce neuropathic pain. Measurements and a visual scale will track pain severity. The study will also assess a hybrid biomarker to distinguish between active and placebo treatments.
Cannabinoid
Nabilone for Diabetic Neuropathy
Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.
Bicifadine for Diabetic Neuropathy
To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of pain intensity) associated with diabetic periperal neuropathy in adult outpatients. To compare the tolerability of two dosages of bicifadine SR with placebo in adult outpaitens treated for chronic neuropathic pain for 14 weeks associated with diabetic peripheral neuropathy.
Procedure
Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain
This trial is testing the effects of the study drug on neuropathic pain caused by chemotherapy. It will last 13 weeks and participants will be randomly assigned to either the study drug or placebo group.
Spinal Cord Injury Clinical Trials
View 15 Spinal Cord Injury medical studies.
Behavioural Intervention
Exercise Intervention for Neuropathic Pain After Spinal Cord Injury
This trial is studying how functional electrical stimulation (FES) can help people with spinal cord injuries by reducing pain, improving brain function, and increasing the size of the hippocampus.
Behavioural Intervention
Immersive Virtual Reality for Neuropathic Pain
The investigators hypothesize that SCI patients using immersive IVR training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life.
Deep Brain Stimulation
DBS for Chronic Pain
This trial is testing a new way to provide deep brain stimulation (DBS) for people with chronic pain that has not been relieved by other treatments. DBS involves surgically placing a small device in the brain that sends electrical signals to specific areas. The goal of this trial is to find out whether DBS is more effective when it is turned on only when needed, rather than continuously.
Phase 3 Neuropathic Pain Clinical Trials
View 80 phase 3 neuropathic pain medical studies.
Cannabinoid
Nabilone for Diabetic Neuropathy
Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.
Behavioural Intervention
Immersive Virtual Reality for Neuropathic Pain
The investigators hypothesize that SCI patients using immersive IVR training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life.
Neuropathic Pain Clinical Trials With No Placebo
View 80 neuropathic pain medical studies that do not have a placebo group.
Behavioural Intervention
Virtual Reality (VR) Self-Hypnosis Software for Musculoskeletal Pain
This trial is looking at whether a self-hypnosis software, used with a virtual reality device, can help to relieve pain in HIV patients. The study will assess the safety, usability, and effectiveness
Behavioural Intervention
Scrambler Therapy for Neuropathic Pain
This trial tests if a new therapy (ST) can reduce pain in people w/ corticobasal syndrome. Patients are randomly assigned TENS or ST, ECG electrodes placed, & treatment until relief is obtained. Results will show if ST is an effective pain relief option.
View More Neuropathic Pain Trials
See another 51 medical studies focused on neuropathic pain.
Frequently Asked Questions
Introduction to neuropathic pain
What are the top hospitals conducting neuropathic pain research?
When it comes to finding new solutions for those suffering from neuropathic pain, several top hospitals are leading the way. Stanford University, located in both Stanford and Palo Alto, California, is at the forefront of this field with a total of five active neuropathic pain trials between its two campuses. Since recording their first trial in 2016 (Stanford) and 2022 (Palo Alto), they have demonstrated a commitment to advancing our understanding of this condition. Meanwhile, in Miami, Florida, the University of Miami has also emerged as an influential institution with three ongoing neuropathic pain trials and a record of four completed studies since initiating their first trial in 2017.
Heading north to Minneapolis, Minnesota, we find another prestigious facility making strides in neuropathic pain research. The University of Minnesota has successfully conducted five clinical trials on this subject thus far while currently running three more investigations. Their dedication began in 2016 when they embarked on their inaugural neuropathic pain study. Rounding off these pioneering hospitals is Massachusetts General Hospital in Boston—this renowned establishment has made significant contributions to addressing neuropathic pain through six completed clinical trials and continues their efforts with three ongoing studies since delving into this area back in2006.
These medical centers collectively represent beacons of hope for individuals enduring the challenges posed by chronic neuropathic pain—a condition that can greatly affect one's quality life.Through innovative research endeavors carried out across different locations nationwide,a shared goal remains: alleviating suffering,promoting better treatments,and improving overall well-being.As these institutions push boundaries and expand knowledge about managing patients' conditions,the potential for breakthroughs emerges ever closer,fueling optimism among countless individuals who eagerly await advancements that might transform their lives forever
Which are the best cities for neuropathic pain clinical trials?
In the realm of neuropathic pain clinical trials, several cities stand out as leading centers for research. Among them are Boston, Massachusetts with 11 active trials investigating treatments like Gabapentin and Qutenza (capsaicin) 8% topical system. Houston, Texas also joins the ranks with 10 ongoing studies focused on interventions such as Tetrodotoxin for injection. Additionally, Miami, Florida contributes to the field with 8 active trials exploring innovative solutions like Transcranial direct electrical stimulation (tDCS). These cities serve as key hubs where individuals suffering from neuropathic pain can find opportunities to participate in cutting-edge clinical trials that could potentially revolutionize treatment options and improve their quality of life.
Which are the top treatments for neuropathic pain being explored in clinical trials?
Clinical trials investigating treatments for neuropathic pain have identified several promising options. [18F]FTC-146, a drug first listed in 2018, is currently being explored in two active trials dedicated to neuropathic pain. Another effective approach is spinal cord stimulation, which has shown positive results in five all-time trials and is currently under investigation in two ongoing studies. Additionally, ketamine infusion therapy has emerged as a potential treatment option with one active trial and one all-time trial focused on neuropathic pain since its recent introduction in 2021. These innovative approaches offer hope for individuals suffering from this challenging condition.
What are the most recent clinical trials for neuropathic pain?
Exciting developments are underway in the field of neuropathic pain management, with recent clinical trials offering potential breakthroughs. One such trial explores the effectiveness of RTA 901 Dose 1 as a treatment for neuropathic pain. Additionally, Gabapentin has shown promising results in Phase 3 trials, indicating its potential to provide relief for individuals suffering from this condition. Another avenue being explored is the use of THC (Dronabinol) and CBD/PEA as alternative therapies for neuropathic pain management. Moreover, AFA-281 shows promise in early-phase studies as a potential solution to alleviate neuropathic pain symptoms. These ongoing trials hold great promise and offer hope to those experiencing the debilitating effects of neuropathy-related discomfort.
What neuropathic pain clinical trials were recently completed?
In recent years, numerous clinical trials have been conducted to explore potential treatments for neuropathic pain. Notable among these trials are the completion of a study on LY3526318 by Eli Lilly and Company in January 2022. In December 2020, Lexicon Pharmaceuticals concluded their trial on LX9211, while Eliem Therapeutics (UK) Ltd. completed a trial on ETX-018810 in November of the same year. Other completed trials include studies on Naloxone Hydrochloride 0.4 MG/ML by Seema Capoor in October 2020, Galcanezumab by Duke University and BAY1817080 by Bayer both in July 2020, as well as LY3016859 and LX9211 high dose by Eli Lilly and Company and Lexicon Pharmaceuticals respectively also in July 2020. Furthermore, Aptinyx finalized a trial on NYX-2925 at a dosage of 50 mg back in November 2019. These collective efforts reflect the ongoing commitment to finding effective therapies for patients suffering from neuropathic pain.